

1 Expression and Purification of a Mammalian Protein: Cytosolic 2 Domain of IRE1 α from Insect Sf21 Cells

3 Amrita Oak ¹, Grace Jansen ¹ and Christina Chan ^{1,2, *}

4 ¹ Dept. of Chemical Engineering and Materials Science, Michigan State University;

5 ² Dept. of Biochemistry and Molecular Biology, Michigan State University

6 * Correspondence: krischan@egr.msu.edu;

7 **Abstract:** Eukaryotic proteins can be expressed in different heterologous systems.
8 However, mammalian proteins in general have specific post-translational processing
9 requirements that may not be fulfilled by a regular bacterial expression system. In this study,
10 we use an insect cell system to express a mammalian protein of interest. *Spodoptera*
11 *frugiperda* (Sf21) cells were used in conjunction with a baculoviral expression system to
12 produce the cytosolic domain (CD) of IRE1, an endoplasmic reticulum (ER) stress sensor
13 protein. Inositol Requiring Enzyme 1 (IRE1) is a dual function kinase and endoribonuclease
14 protein that cleaves X-box binding protein (XBP1) mRNA. We used the pFastBac plasmid
15 to insert the coding sequence into a recombinant bacmid shuttle vector which was then used
16 to infect Sf21 cells. The expressed protein was then purified with an MBPTrap column to
17 obtain >85% pure protein.

18 **Keywords:** Sf21 cells; baculoviral expression; IRE1; pFastBac; MBP-tagged protein
19 purification
20

21 1. Introduction

22 Heterologous expression of proteins is defined as the expression of proteins in an
23 organism that does not naturally express the protein. The different systems in use for such
24 purposes can be broadly classified as bacterial, yeast, insect and mammalian systems. Cells
25 in culture can be manipulated to express the protein of interest in transient or stable mode.
26 Some factors that need to be considered while choosing the expression system are the
27 required yield of the protein, post-translational modifications, functionality, and speed of
28 expression.

29 Proteins of prokaryotic origin are best expressed in bacterial systems. *E. coli* can express
30 and adequately process prokaryotic proteins and is the go-to system for cheap, scalable and
31 high yield expression. If the expression of eukaryotic proteins is required, additional factors
32 need to be taken into consideration. The most important factor would arguably be the level
33 of post-translational modifications (PTM) required for a functional form of the protein.
34 Proteins requiring extensive PTMs will not be processed correctly in bacterial systems and
35 will most likely aggregate in inclusion bodies[1]–[3]. Adding a fusion protein tag to the
36 protein of interest may sometimes help to resolubilize the proteins. However, in the interest
37 of saving time and effort, it is advisable to switch to higher eukaryotic systems such as insect
38 or mammalian cells. Another advantage to eukaryotic systems is the presence of extensive
39 protein folding machinery that is vital for the function of the protein [4].

40 **Table 1** compares the different heterologous protein expression systems with respect to
41 the type of protein, post-translational modifications and ease of large-scale production [5]–
42 [10].

43

44

45

46 **Table 1: Characteristics of heterologous protein expression in bacterial, yeast, insect**
 47 **and mammalian cell systems ranked according to desirability**
 48

	Bacterial	Yeast	Insect	Mammalian
Type of protein				
Prokaryotic	Y	Y	Y	Y
Eukaryotic	Y	Y	Y	Y
Secreted	Y	Y	Y	Y
Post-translation modifications				
Phosphorylation	Y	Y	Y	Y
Glycosylation	N	Y	Y	Y
Acetylation	N	Y	Y	Y
Acylation	N	Y	Y	Y
Refolding required?	Y	Y	N	N
Production				
Cell growth	Rapid (30 mins)	Rapid (1.5 hrs)	Moderate (18 hrs)	Slow (24hrs)
Yield	High	High	Moderate	Low
Time to expression	Rapid	Moderate	Moderate	High
Cost	Low	Expensive	Expensive	Very expensive
Ease of scale-up	Easy	Easy	Difficult	Very difficult

49




50
51

52 Bacterial systems have desirable characteristics for large scale production but are not
 53 able to process and correctly fold proteins requiring extensive PTMs [11]. Depending on the
 54 application of the protein, Chinese hamster ovary (CHO) or Human embryonic kidney (HEK
 55 293) cells are typically the system of choice for eukaryotic proteins [12]. This is true,
 56 especially for therapeutic proteins or antibodies. However, the yield is very low compared to
 57 insect or bacterial cells – typically on the order of 100mg/L of expressed protein [13]. The
 58 level of protein expression is higher in insect cells up to 100mg/ L [14], [15].

59 Insect cells and mammalian systems have a wide range of post-translational
 60 modifications. An excellent tool to determine all possible post-translational modifications of
 61 a protein of interest is dbPTM (<http://dbptm.mbc.nctu.edu.tw/>). Insect and mammalian
 62 systems are both capable of all PTMs with one exception. Insect cells and mammalian cells
 63 have similar phosphorylation and O-linked glycosylation patterns. They can authentically
 64 process phosphorylation modifications, partly due to the presence of phosphatases. However,
 65 in terms of N-glycosylation, proteins in insect cells are high-mannosylated while mammalian
 66 cells have a complex glycosylation pattern [4], [12]. **Figure 1** depicts the difference in N-
 67 linked glycosylation patterns in insect cells vs. mammalian cells. Regular insect Sf9 and Sf21
 68 cells will have a high mannose pattern of glycosylation but mimic Sf9 (available from
 69 ThermoFisher) cells are engineered to make complex N-glycans with terminal sialic acid.
 70 Varied and complex sugars such as N-acetylneuraminic acid, galactose, fucose, mannose are
 71 added in mammalian cells in a branched configuration as opposed to the addition of only
 72 mannose residues in insect cells.

73
74
75



76
77
78
79
80
81
82
83
84
85
86
87
88
89
90
91
92
93
94
95
96

Figure 1: N-linked glycosylation patterns for insect cells and mammalian cells

In this study, we developed a protocol to express the Inositol Requiring Enzyme-1 α (IRE1 α) protein, an ER stress sensor. IRE1 is a type I transmembrane protein primarily composed of three domains, the luminal domain, a transmembrane domain and cytosolic domain (CD)[16].

IRE1 α is a bifunctional protein with kinase and endoribonuclease activity on the CD. We have developed a protocol to produce IRE1 α -CD (547-977 aa) in insect Sf21 cells using baculovirus expression. IRE1 α has been expressed in *E. coli* cells in our lab (unpublished data) as well as by other groups[17], [18]. However, IRE1 α expressed in *E. coli* and yeast systems is in a hyperphosphorylated state[18], [19]. All the purification methods used thus far for purifying this protein have used the 6X His tag. The cell line used was Sf9 [18], [22]. However, there are no detailed methods or protocol papers published for this procedure, that is, using the Sf9 cells and 6X His tag method.

Post-translational modifications for IRE1 were predicted using algorithms developed by the Center for Biological Sequence Analysis, Technical University of Denmark (<http://www.cbs.dtu.dk/> [1]). The predicted N-glycosylation, O-glycosylation, C-mannosylation and glycation sites are scored for the likelihood of modification (**Table 2**). The scores that cross the threshold (which is set by the algorithm at 0.5) are denoted as “positive” hits.

97 **Table 2: Predictions for O-glycosylation, C-mannosylation, N-glycosylation and**
 98 **glycation sites on CD-IRE1.**

O-glycosylation			
start	end	score	comment
2	2	0.792	#POSITIVE
3	3	0.796	#POSITIVE
5	5	0.791	#POSITIVE
15	15	0.189	
16	16	0.506	#POSITIVE
24	24	0.111	
38	38	0.015	
61	61	0.043	
73	73	0.040	
85	85	0.006	
102	102	0.018	
121	121	0.110	
126	126	0.102	
127	127	0.213	
128	128	0.181	
135	135	0.052	
151	151	0.107	
164	164	0.034	
178	178	0.107	
180	180	0.741	#POSITIVE
183	183	0.643	#POSITIVE
188	188	0.111	
198	198	0.148	
206	206	0.026	
208	208	0.047	
213	213	0.013	
223	223	0.070	
226	226	0.040	
232	232	0.064	
245	245	0.252	
276	276	0.510	#POSITIVE
288	288	0.454	
300	300	0.102	
300	300	0.102	

C-mannosylation			
start	end	score	comment
191	191	0.18	.
287	287	0.271	.

Glycation			
start	end	score	comment
22	22	-0.943	.
28	28	-0.707	.
53	53	0.801	YES
87	87	-0.875	.
110	110	0.832	YES
144	144	-0.529	.
158	158	0.699	YES
160	160	0.863	YES
170	170	-0.773	.
171	171	0.83	YES
202	202	-0.95	.
231	231	-0.962	.
253	253	-0.799	.
265	265	0.806	YES
273	273	-0.94	.
282	282	-0.878	.
291	291	-0.83	.

N-glycosylation			
start	end	score	comment
204	204	0.5427	+

99
100

101 **2. Experimental Design**

102 *2.1 Materials*

103 All the materials are listed separated by each sub-section of the procedure.

104 Cloning of IRE1 α -CD into pFastBac plasmid

- 105 i. pFastBac His6 MBP N10 TEV LIC cloning vector (4C) (Addgene plasmid #30116)
- 106 ii. SspI-HF (New England Biolabs, cat # R3132S)
- 107 iii. CutSmart buffer (New England Biolabs cat# B7204S)
- 108 iv. QIAquick PCR Purification Kit (Qiagen, cat# 28104)
- 109 v. Deoxynucleotide (dNTP) set includes dGTP, dCTP (New England Biolabs, cat #
- 110 N0446S)
- 111 vi. Bovine Serum Albumin (BSA), Molecular Grade (New England Biolabs, cat#
- 112 B9000S)
- 113 vii. T4 DNA Polymerase (New England Biolabs, cat# M0203S)
- 114 viii. Q5 High Fidelity 2X Master Mix (New England Biolabs, cat# M0492S)
- 115 ix. OneShot Top10 chemically competent *E. coli* DH5 α (ThermoFisher, cat# C404003)
- 116 x. Luria Broth (Sigma-Aldrich, cat# L3397)
- 117 xi. Luria Agar (Sigma-Aldrich, cat# L3272)
- 118 xii. LB agar plates containing ampicillin (Sigma-Aldrich, cat # L5667-10EA)

119

120 Preparation of recombinant bacmid

- 121 xiii. MAX Efficiency *E. coli* DH10Bac competent cells (ThermoFisher cat# 10361012)

122 xiv. Antibiotics and their stock solutions are listed in **Table 3**. Aliquot and store at -20°C .

123

124 **Table 3: Antibiotic concentrations and stock solutions**

Component	Dissolve in	Company (Cat. No)	Stock conc.	Special considerations
Kanamycin	Water	Sigma (60615)	50 mg/mL	
Tetracycline	Ethanol	Sigma (87128)	10 mg/mL	Light sensitive
Gentamicin	Water	Sigma (G1914)	7 mg/mL	
X-gal**	Dimethyl formamide	Sigma (XGAL-RO)	20 mg/mL	Light sensitive, DO NOT filter sterilize, Make solution in a glass vial or polypropylene tube
IPTG	Water	Sigma (I6758)	200 mg/mL	Filter sterilize

125

** There are other options for X-gal such as *Bluo-gal* (ThermoFisher, cat # 15519028). It is more expensive but more sensitive and turns a deeper, more obvious blue that aids in colony identification**

126

127

128

xv. S.O.C medium (ThermoFisher cat# 15544034)

129

xvi. PureLink HiPure Plasmid Miniprep Kit (Invitrogen, cat# K210002)

130

Transfection of recombinant bacmid into Sf21 cells

131

i. Sf-900-III serum-free media (ThermoFisher, cat# 12658019)

132

ii. Cellfectin II reagent (ThermoFisher, cat# 10362100)

133

iii. Gelcode Blue Stain Reagent (ThermoFisher, cat# 24590)

134

iv. IRE1 α (14C10) Rabbit mAb (Cell Signaling Tech, cat# 3294)

135

Protein purification using MBPTrap column

136

v. Xtractor cell lysis buffer (Takara, cat# 635671)

137

vi. cOmplete, Mini, EDTA-free protease inhibitor cocktail (Sigma, cat# 11836170001)

138

vii. MBPTrap HP column (GE, cat# 28-9187-78)

139

viii. D-(+)- Maltose monohydrate (Sigma, cat# 63418-25G)

140

ix. Tris-Cl (Sigma, cat # 10812846001)

141

x. NaCl (Sigma, cat # S3014)

142

xi. Dithiothreitol (DTT) (Sigma, cat# DTT-RO)

143

xii. EDTA (Sigma, cat # 324504)

144

xiii. Phosphate buffered saline (PBS) (Sigma, cat# P7059-1L)

145

xiv. Binding buffer for MBPTrap HP column: 20 mM Tris-HCl, 200 mM NaCl, 1 mM DTT, 1 mM EDTA, pH 7.4

146

xv. Elution Buffer for MBPTrap HP column: Binding buffer + 10mM maltose

147

xvi. Regeneration buffer: 0.5M NaOH

148

149

150

3. Procedure

151


Figure 2 depicts a flowchart of the steps involved in the expression and purification of

152

IRE1 α -CD in Sf21 cells using baculoviral vectors. The procedure is divided into 5 subunits.

153

The time required for each subunit is indicated in brackets in the left column (**Figure 2**).



154

155 **Figure 2: Flowchart for all the steps involved in the expression and purification of**
156 **proteins from Sf21 cells**

157 *3.1 Cloning of IRE1 α -CD into pFastBac plasmid*

158 *Note:*

159 pFastBac His6 MBP N10 TEV LIC cloning vector (4C) was a gift from Scott Gradia
160 (Addgene plasmid #30116; <http://n2t.net/addgene:30116>; RRID: Addgene_30116). Another
161 version of this plasmid (5C) is available so that two proteins can be expressed simultaneously.
162 The sequence for IRE1 α - CD was obtained from NCBI (Gene id: 2081). Primers were
163 designed to clone the CD fragment from 547 aa-977 aa from a pCDNA-hIRE1 plasmid
164 containing a full-length IRE1 coding sequence.
165

165

166 **Table 4: PCR primers for insertion of IRE1-CD (547aa-977aa) into pFastBac plasmid**

CD_IRE1_forward	5'- <u>TACTTCCAATCCAATGCAGGCAGCAGCCCCTCCCTGGAAC</u> -3'
CD_IRE1_reverse	5'- <u>TTATCCACTTCCAATGTTATTAGAGGGCGTCTGGAGTCAC</u> -3'

167

168

169

170

171

172

173

174

175

Table 4 shows the primers designed for the insertion of IRE1 α -CD into the empty pFastBac plasmid. The underlined tag on each primer is to facilitate ligation independent cloning (LIC) and is specific to the pFastBac backbone. The rest of the primer is specific to the insert coding sequence (CDS). The LIC technique makes use of the endonuclease activity of T4 DNA polymerase to generate sticky overhangs for ligation between the vector plasmid and insert DNA. This technique avoids the use of ligases.

176

Protocol:

Preparing the vector pFastBac plasmid

177

178

179

180

181

- i. Linearize the plasmid with SspI-HF (NEB) (**Table 5**). The high-fidelity (HF) versions of restriction enzymes are faster and more efficient. Incubate at 37°C for 15 mins – 2 hrs to completely digest all the plasmid DNA. Heat inactivation is performed for 20 mins at 65°C.

Table 5: Restriction digestion with SspI-HF

Component	Amount	Volume (μ L)
pFastBac plasmid DNA (250ng/ μ L)	1 μ g	4
10X CutSmart buffer	Final concentration 1X	5
SspI-HF	10 units	1
Water	Make up to 50 μ L	40

182

183

184

185

186

187

188

- ii. Use a PCR purification kit (QIAquick) to purify the large linearized fragment of plasmid DNA.
- iii. To create pFastBac vector overhangs, mix the following components in PCR tubes, the order of addition is as listed (T4 DNA polymerase is added last) (**Table 6**). Incubate at 12°C for 30 minutes followed by heat inactivation at 75°C for 20 minutes.

Table 6: Mix to create pFastBac vector overhangs

Reagent	Final conc.	Volume (μ L)
10x NEB 2.1	1x	4
Eluted linearized pFastBac DNA	10-50 ng/ μ L	20-30
dGTP (100mM)	2.5 mM	1
DTT (100mM)	5 mM	2
BSA (10 ug/ μ l)	0.25 μ g/ μ L	0.6
T4 DNA polymerase	0.075 units/ μ L	1
Sterile dH ₂ O to 40ul		

189

190

191

192

193

Preparing the insert IRE1 α -CD

- iv. Set up a PCR to amplify the IRE1 α -CD insert using the primers in **Table 4** as outlined in **Table 7**. Confirm amplification by running the PCR product on a 1.5% agarose gel.

194

Table 7: PCR mix for preparing IRE1 α -CD insert

Component	Volume (μ L)
Q5 2X Master Mix	25
CD_IRE1_forward primer (10 μ M)	2
CD_IRE1_reverse primer (10 μ M)	2
pCDNA-hIRE1 (50 ng/ μ L)	1
Nuclease free water (make up to 50 μ L)	20

195 The PCR program should be run for 98°C 1 min, followed by 35 cycles of 98°C for 30
196 sec, 61°C for 10 sec, 72°C for 90 sec, and a final extension of 72°C for 5 mins.

- 197 v. Create the insert overhangs in a way similar to the vector overhangs in the presence of
198 dCTP (instead of dGTP).
199 vi. After heat inactivation, mix both vector and insert together (1:3 ratio). The total volume
200 of the combined vector and insert should be between 5-10 μ L. Incubate for 5 mins at
201 room temperature and then add 1 μ L of 25 mM EDTA followed by another incubation
202 for 5 mins.
203 vii. Transform 2 μ L of this mixture into competent OneShot Top10 *E. coli* DH5 α (100 μ L),
204 spread onto LB agar plates containing 100 μ g/mL ampicillin and incubated at 37°C for
205 16-24 hrs.
206 viii. Select individual colonies (5-10) and prep the plasmid DNA. Confirm the insertion of
207 IRE1 α - CD by DNA sequencing using primers specific to the IRE1 α -CD sequence (seq
208 for- 5'- aagcagctccagtcttccaggac-3')

210 3.2 Preparation of recombinant bacmid

211 *Note:*

212 Once the insert has been cloned into the pFastBac empty plasmid, it needs to be
213 transformed into *E. coli* DH10Bac cells to form the recombinant bacmid. *E. coli* DH10Bac
214 competent cells are sold by ThermoFisher. The genotype is F-mcrA Δ (mrr-hsdRMS-
215 mcrBC) Φ 80lacZ Δ M15 Δ lac X74 recA1 endA1 araD139 Δ (ara, leu)7697 galU galK λ - rps
216 L nupG /pMON14272 / pMON7124. DH10Bac cells have a baculovirus shuttle vector and a
217 helper plasmid. This machinery is required for the generation of recombinant bacmid after
218 transformation of pFastBac-IRE1 α -CD into the cells. The baculovirus shuttle vector
219 (bMON14272) also encodes kanamycin resistance, and the helper plasmid (pMON7142) has
220 tetracycline resistance. The presence of the Φ 80lacZ Δ M15 Δ lac marker enables the use of
221 blue/white colony screening to determine integration of the insert into the bacmid. pFastBac
222 has the Tn7 element which includes the polyhedrin promoter, the gene of interest and
223 gentamicin resistance.

224 It is also possible to use regular *E. coli* DH10Bac cells and make them chemically
225 competent (see **Supplemental file**).

226

227 **Protocol:**

- 228 i. Dissolve LB agar powder in water and autoclave at 121°C for 15 mins.
229 ii. Let it cool to 55°C (there should be no lumps of agar).
230 iii. Add all the antibiotics and chemicals in the working concentrations listed in **Table 8**.

231

232

Table 8: Working concentrations of antibiotics

Component	Stock conc.	Working conc.	Dilution
Kanamycin	50 mg/mL	50 μ g/mL	1:1000
Tetracycline	10 mg/mL	10 μ g/mL	1:1000

Gentamicin	7 mg/mL	7 µg/mL	1:1000
X-gal	20 mg/mL	200 µg/mL	1:100
IPTG	200 mg/mL	40 µg/mL	1:200

233

234 iv. Let harden, store at 4°C in the dark.

235 v. Thaw a vial of competent *E. coli* DH10Bac cells on ice in a 15 mL round bottom
236 sterile polypropylene tube.

237 **Do not use 1.7 mL or 2 mL microcentrifuge tube**

238 vi. Add 100ng pFastBac-IRE1-CD plasmid DNA to the vial.

239 vii. Incubate on ice for **30 mins**.

240 viii. Heat shock for **45 s** at **42°C**.

241 ix. Transfer tubes back on ice and chill for 5 mins.

242 x. Add **900 µL** SOC medium.

243 xi. Incubate tubes in a shaking incubator, 37°C at 200 rpm for at least **4 hrs**.

244 **This 4 hr long outgrowth step is necessary to allow the bacteria to generate the
245 antibiotic resistance proteins encoded on the plasmid backbone**

246 xii. Make three 10-fold serial dilutions of 800 µL cells. Plate 100uL of each dilution onto
247 LB plates with kanamycin, tetracycline, gentamicin, X-gal and IPTG.

248 xiii. Incubate plates at 37°C for **48 hrs** to allow enough time for colony formation and color
249 development. Pick white colonies.

250 **Do not pick colonies before 48 hrs because it may be difficult to distinguish between
251 white and blue colonies**

252 **Pick colonies that are large and well isolated. Avoid picking colonies that are gray or
253 darker in the center as they may contain a mixture of empty bacmid and recombinant
254 bacmid**

255 xiv. Replate selected colonies for an additional round of selection on fresh LB agar plates
256 overnight at 37°C.

257 xv. Once the white phenotype is confirmed, inoculate in LB media with kanamycin,
258 gentamicin, and tetracycline and grow overnight.

259 xvi. Isolate recombinant bacmid DNA using Purelink HiPure Plasmid Kit by Invitrogen with
260 a modified protocol (see **Supplemental file**).

261

262 3.3 Transfection of recombinant bacmid into Sf21 cells

263 *Note:*

264 Sf21 cells are suspension cells grown at 28°C, without the need for CO₂ incubators. They
265 are grown in Sf-900 III media. The media can be supplemented, if needed, with serum but
266 bovine serum should not be used (fetal bovine serum (FBS) is preferred). The serum needs
267 to be inactivated to inactivate complement fragments that can inactivate baculoviruses.
268 Transfection reagents can be lipid based (e.g. cellfectin, fugene). Calcium chloride can be
269 used for baculovirus transfection, but it has less efficiency than lipid-based reagents.

270

271 **Protocol:**

272 *Transfection of bacmid into Sf21 cells*

273 i. A day before transfection, passage Sf21 cells so that they are at a density of 3 x 10⁵
274 cells/mL.

275 **Actively dividing cells have a higher transfection efficiency and produce more protein**

276 ii. Plate cells at a concentration of 8 x 10⁵ cells/well of a 24-well plate.

277 iii. Allow the cells to attach for 1 hr and replace media with fresh media (without FBS).

278 iv. Use 2 µg of bacmid DNA per well. Dilute in 75 µL of Sf 900-III media. Incubate for
279 15 mins.

- 280 v. Use 8 μ L of cellfectin II in 75 μ L media. Incubate for 15 mins.
281 *Make sure the cellfectin II is mixed thoroughly before use, but do not vortex the tube*
282 vi. Mix together the two tubes and incubate for 15-30 mins.
283 vii. Add mixture dropwise to the wells of the 24-well plate.
284 viii. 24 hrs later, replace transfection media with fresh SF-900 III media containing 10%
285 FBS.
286 *Serum proteins in FBS act as substrates for proteases*
287 ix. Check for signs of infection (SIF) after 24 hrs up to 96 hrs.
288 *SIF may not be obvious in P0 infection so continue infection for 5 days and collect the
289 supernatant and re-infect for 5 more days to amplify the viral stock*
290 x. After changing media, collect supernatant after every 24 hrs for 24, 48, 72 and 96 hrs.
291 This supernatant is the P0 viral stock. Store at 4°C in the dark.
292 xi. Use the P0 viral stock to infect newly plated Sf21 cells to generate P1 stock. Add 150
293 μ L of P0 stock dropwise on top of the cells (plated in a 6-well plate), gently swirl a few
294 times and incubate the plate at 28°C.
295 xii. Look for SIF in 24 hours post infection time. After 5 days, collect only P1 viruses with
296 SIF and store viral stocks in the dark at 4°C.
297 xiii. In a similar fashion, collect P2, P3 and P4 stocks for increased baculoviral titer with an
298 increasing number of cells infected (6-well plate \rightarrow 150 cm dish \rightarrow T25 flask). Store all
299 at 4°C protected from light.

300

301 *Scale-up of heterologous protein expression*

- 302 i. Seed Sf21 cells in a T75 (vented) flask as described in the transfection procedure. Make
303 sure they are actively dividing cells in the log phase of growth.
304 ii. Add 150 μ L of the collected P1 stock.
305 iii. Incubate at 27°C for 5 days or until 30-40 % of the cells have lysed.
306 iv. Collect cells as well as supernatant. **This will be the P2 viral stock.**
307 v. Use P2 viral stock to infect spinner flasks with Sf21 cells.
308 vi. If no signs of infection are observed, infect Sf21 cells with the P2 stock of baculoviruses
309 and collect the P3 viral stock (see **Figure 5** for SIF). We concentrated the baculovirus
310 viral supernatants with successive passages (P1,P2,P3) and used the passage that gave
311 us visible signs of infection at 24 hrs with expression of protein. The viral titer
312 (expressed as plaque-forming units/mL or pfu/mL) can also be determined with a plaque
313 assay. Briefly, cells in a tissue culture dish are infected and overlaid with agarose. After
314 the cells are grown for about 10 days, the plaques can be counted to determine the
315 pfu/mL concentration.
316

317 *3.4 Purification of MBP fusion protein*

318 *Note:*

319 For this protocol, use Sf21 cells infected with P3 stock of baculovirus for 96 hrs. The cell
320 pellet is collected and lysed with Xtractor buffer, and an MBPTrap column is used to extract
321 MBP-tagged IRE1 α -CD. The MBP tag can be cleaved from the protein by incubating with 1
322 unit of AcTEV protease (ThermoFisher, cat# 12575015) for 1 hr at 30°C for each 3 μ g protein.
323

324


324 **Protocol:**

- 325 i. Prepare Xtractor buffer with protease inhibitor of choice. In this purification protocol, we
326 used cOmplete EDTA free protease inhibitor cocktail.
327 ii. Pellet Sf21 cells at 100 x g for 15 mins, remove supernatant media and wash pellet once
328 with phosphate buffered saline (PBS). Add 5 mL Xtractor buffer to 1 g cell pellet.

- 329 iii. Mix vigorously by vortexing and rock at room temperature for 15-30 mins. Make sure
330 that cell lysis is complete by observing under the microscope.
331 iv. Centrifuge at 16,000 g for 20-30 mins to pellet the cell debris.
332 v. Take the clarified supernatant and filter through a 0.22 μm filter immediately before
333 loading onto the MBPTrap HP column.
334 vi. Prior to loading the clarified lysate, equilibrate the MBPTrap HP column with 7 column
335 volumes (CV) of binding buffer at a flow rate of 1 mL/min
336 vii. Load clarified lysate onto the column. The binding capacity of the 1 mL MBPTrap HP
337 column is protein dependent but can bind approximately to 5 mg-7 mg of MBP-tagged
338 protein. The flow rate should be decreased to 0.5 mL/min.
339 viii. Wash with 10 CV of binding buffer at a flow rate of 1 mL/min. If real-time A280 readings
340 are possible, wash until no discernible absorbance at 280 nm is observed.
341 ix. Add 5 CV of elution buffer at a reduced flow rate of 0.5 mL/min, and assay elute fractions
342 to determine fractions with the highest concentration of the protein of interest with a
343 Bradford or BCA assay.
344 x. Regenerate the column with 3 CV distilled water followed by 3 CV of 0.5 M NaOH.
345 Wash away the NaOH with 5 CV distilled water. The column is now ready to be used
346 again.
347

348 4. Expected Results

349 The pFastBac- IRE1 α -CD plasmid features are shown in **Figure 3** [20]. IRE1 α -CD is
350 fused to the C-terminus of an MBP protein under the polyhedrin promoter. A 6X His tag is
351 also present at the N-terminal of the MBP protein. The MBP protein and IRE1 α -CD coding
352 sequences are separated by a Tobacco Etch Virus (TEV) protease site. The plasmid has an
353 ampicillin (amp) and gentamicin (gent) selection marker for selection during the preparation
354 of recombinant bacmid. The pFastBac backbone has a Tn7att transposition element that
355 guides the insertion of the coding sequence into the bacmid. After transformation into *E. coli*
356 DH10Bac, colonies were grown for 48 hrs. Colonies show up within 24 hrs but take an
357 additional day to develop a blue color. Large white colonies were selected and re-streaked
358 onto a Tet-Kan-Gent-IPTG-X-gal plate.




359
360

Figure 3: Plasmid map for pFastBac-IRE1 α -CD

361
362
363
364
365
366
367
368


After this additional round of selection, a colony PCR was performed to make sure that IRE1 α -CD was incorporated into the recombinant bacmid (**Figure 4**). Primers specific to an internal region in IRE1 α -CD were used. As expected, a band was seen in all of the white colonies picked, indicating that the gene of interest was inserted in the bacmid. Bacmids were prepped and sent for DNA sequencing. Once the IRE1 α -CD sequence was confirmed, glycerol stocks were made for future use (see **Supplemental file**).



369
370
371
372
373
374
375
376
377
378

Figure 4: Colony PCR of white *E. coli* transformant colonies

The recombinant bacmid was extracted from *E. coli* DH10Bac cells and precipitated with 100% isopropanol to obtain pure bacmid samples. Sf21 cells were transfected and monitored for signs of infection for 5 days and multiple passages of viral titer. **Figure 5** shows the Sf21 cells changing on infection with P3 baculoviruses. The cells become larger in size, and the nuclei appear to occupy more of the cell. The Sf21 cells show more granularity as the infection progresses.




379
380
381
382
383
384
385
386
387
388
389
390
391
392
393
394
395

Figure 5: Signs of infection in untransfected Sf21 cells (left) and P3 treated Sf21 cells (right) for 24 hrs. Scale bar = 45 μ m

We checked the expression of IRE1 α -CD after transfection by collecting cell lysate after P0 and P1 infections. **Figure 6** shows a GelCode Blue-stained SDS-PAGE (8%) of cell lysates after transfection and infection with baculoviruses to express IRE1 α -CD. As evident in the figure, the IRE1 α -CD protein is produced along with other contaminating insect cell proteins, also stained by GelCode Blue and therefore needs to be purified for downstream assays. The proportion of IRE1 α -CD protein expressed in P1 infected cells was more than P0 infected cells, reflecting the higher concentration of baculoviral titer. The baculovirus stock was amplified to P3 to obtain high protein expressing infected Sf21 cells.

The P3 viral supernatant was collected, filtered with a 0.22 μ m filter and stored at 4 $^{\circ}$ C in the dark for subsequent infection. Sf21 cells were passaged the day before infection so that they were in log phase at a density of 3x10⁵ cells/mL. 150 μ L of P3 supernatant was added for each mL of Sf21 cells. The time required for the expression of a protein depends on each protein of interest expressed.



396

397

398

399

400

401

402

403

404

405

406

407

408

Figure 6: Expression of MBP- IRE1 α -CD protein prior to purification. (Left) SDS-PAGE of total protein lysate for untransfected Sf21 cells, P0 and P1 infected clones 1 and 15. The 100 kDa band is marked and the putative 6X His- MBP- IRE1 α -CD protein band is prominent in P1 infections. (Right) Western blot using an anti-IRE1 antibody

Figure 7 shows the western blot for the different time points throughout protein expression to determine the optimum time point for harvesting the cells. For IRE1 α -CD, in P0 infected cells, maximum expression was observed at 96 hrs. Upon increasing infection titer by using P2 stocks, the overall level of protein expression increased. The optimal time point for harvesting was still after 96hrs of infection.

409

410

411

412

413

414

415

416

417

418

419





Figure 7: Expression of IRE1-CD protein. Western blot showing the time course of protein expression in P0 (left) and P2 (right) infected Sf21 cells using anti-IRE1 α antibody

Once the viral titer and time for expression were optimized, the cell lysates were collected for purification of the protein. We used the MBP tag on the IRE1 α -CD to aid in the purification. Filtered and clarified lysate was run through the MBPTrap column to obtain IRE1 α -CD protein. The protein was of >85% purity based on densitometric analysis of the bands seen in an SDS-PAGE gel. Once IRE1 α -CD is purified, it can be used for binding assays to determine binding partners for the protein [21]. **Figure 8** below shows the various

420 fractions from the purification process outlined in the manuscript. The addition of an MBP-
421 tag makes for a very specific purification. The yield of the expressed protein obtained after
422 purification differs by the plasmids used, by baculoviral stocks and by the type of protein
423 being expressed. The final volume of Sf21 cells infected for scale-up can be adjusted based
424 on the yield of protein required.



CD-IRE1 wild type

425
426 **Figure 8: A GelCode Blue stained SDS-PAGE showing the various fractions from the**
427 **purification procedure of IRE1-CD. FT- Flowthrough, W- Wash fractions, E- Elute**
428 **fractions. The ladder is the Precision Plus blue ladder (Bio-Rad, cat# 1610373). The E2**
429 **fraction shows a pure protein band at ~100kDa as expected**

430
431 Sf21 insect cells combined with the pFastBac baculoviral system make a very robust,
432 optimizable system for expression of eukaryotic proteins. MBP-IRE1 α -CD was successfully
433 expressed and purified from Sf21 cells. This protocol can be easily modified to express any
434 mammalian protein in Sf21 insect cells by modifying the PCR primers shown in **Table 4** for
435 the desired CDS. Long term expression of the protein can be achieved by making frozen
436 stocks of baculovirus infected Sf21 cells. The MBP tag can be cleaved off using AcTEV
437 protease if it interferes with downstream assays and the protein can be cleaned up using a Ni-
438 NTA column. An AKTA-FPLC automated system can be used to aid in purification of higher
439 volumes of cell lysate. If a secretion tag is used and the protein of interest is secreted in the
440 media, a 5mL MBPTrap column can be used with the AKTA FPLC system to automate the
441 purification process.

442 5. Summary

443 Further characterization of the expressed IRE1 α protein is required to establish its
444 structure, phosphorylation status and *in vitro* XBP1 splicing activity conclusively. The
445 phosphorylation status of the protein can be identified by various methods. Feldman et al.,
446 used mass spectrometry techniques to identify the phosphorylated sites on IRE1 α [22]. This
447 technique in conjunction with a Phos-tag gel would lend more information on the ratio of
448 phosphorylated to unphosphorylated species in the purified protein[23], [24]. Using the Phos-
449 tag ligand developed by Fujifilm Wako-Chem, an SDS-PAGE gel can be used to separate
450 phosphorylated proteins from unphosphorylated forms. The Phos-tag ligand binds to the
451 phosphate group and slows down migration of the phosphorylated band. This leads to a

452 separation of the phosphorylated and unphosphorylated species into separate bands. To
453 confirm that the band pattern is because of distinct phosphorylation, purified protein samples
454 can be treated with λ - phosphatase enzyme with activity towards phosphorylated serine,
455 threonine and tyrosine residues. On treatment and subsequent application to a Phos-tag SDS-
456 PAGE gel, the slower migrating band should disappear. *In vitro* XBP1 splicing can be
457 assayed with a hairpin-RNA cleavage assay or by a fluorescence-based assay with a FRET-
458 paired oligonucleotide [18].

459 If the protein structure needs to be determined, circular dichroism or small-angle X-
460 ray scattering techniques can be used. Circular dichroism is a very useful tool to determine
461 secondary structure as well as native folding of expressed or fusion proteins. Specifically,
462 secondary structure can be determined using far-UV spectra and protein folding
463 characteristics can be determined by monitoring spectra at different temperatures or in the
464 presence of different denaturing agents [25].

465
466

467 **Author Contributions:** Conceptualization, A.O. and C.C.; Methodology, A.O.; Validation, A.O., G.J. and
468 C.C.; Writing—original draft preparation, A.O.; Writing—review and editing, A.O., G.J, C.C.; Funding and
469 Supervision, C.C.

470 **Funding:** This research was funded by National Science Foundation, grant number CBET 1510895, CBET
471 1547518 and CBET 1802992.

472 **Acknowledgments:** The authors would like to thank Dr. Xiangshu Jin, Michigan State University for providing
473 the Sf21 cell line for this work.

474 **Conflicts of Interest:** The authors declare no conflict of interest. The funders had no role in the design of the
475 study; in the collection, analyses, or interpretation of data; in the writing of the manuscript, or in the decision
476 to publish the results.

477
478

479 References

- 480 [1] P. T. Wingfield, “Overview of the Purification of Recombinant Proteins,” *Curr.*
481 *Protoc. Protein Sci.*, vol. 80, p. 6.1.1-6.1.35, 2016.
- 482 [2] S. Ventura, “Sequence determinants of protein aggregation: Tools to increase protein
483 solubility,” *Microb. Cell Fact.*, vol. 4, no. 11, pp. 1–8, 2005.
- 484 [3] U. Rinas and J. E. Bailey, “Protein compositional analysis of inclusion bodies
485 produced in recombinant Escherichia coli,” *Appl. Microbiol. Biotechnol.*, vol. 37, no.
486 5, pp. 609–614, 1992.
- 487 [4] X. Shi and D. Jarvis, “Protein N-Glycosylation in the Baculovirus-Insect Cell
488 System,” *Curr. Drug Targets*, vol. 8, no. 10, pp. 1116–1125, 2007.
- 489 [5] R. Chen, “Bacterial expression systems for recombinant protein production: E. coli
490 and beyond,” *Biotechnol. Adv.*, vol. 30, no. 5, pp. 1102–1107, 2012.
- 491 [6] X. Gao, P. Yo, and T. K. Harris, “Improved yields for baculovirus-mediated
492 expression of human His 6-PDK1 and His6-PKB β /Akt2 and characterization of
493 phospho-specific isoforms for design of inhibitors that stabilize inactive
494 conformations,” *Protein Expr. Purif.*, vol. 43, no. 1, pp. 44–56, 2005.
- 495 [7] S. Müller, T. Sandal, P. Kamp-Hansen, and H. Dalbøge, “Comparison of expression
496 systems in the yeasts *Saccharomyces cerevisiae*, *Hansenula polymorpha*,
497 *Kluyveromyces lactis*, *Schizosaccharomyces pombe* and *Yarrowia lipolytica*. Cloning
498 of two novel promoters from *Yarrowia lipolytica*,” *Yeast*, vol. 14, no. 14, pp. 1267–
499 1283, 1998.
- 500 [8] J. C. Gupta, M. Jaisani, G. Pandey, and K. J. Mukherjee, “Enhancing recombinant
501 protein yields in *Escherichia coli* using the T7 system under the control of heat
502 inducible λ P(L) promoter,” *J. Biotechnol.*, vol. 68, no. 2–3, pp. 125–134, 1999.
- 503 [9] Y. Huang, Y. Li, Y. G. Wang, X. Gu, Y. Wang, and B. F. Shen, “An efficient and
504 targeted gene integration system for high-level antibody expression,” *J. Immunol.*
505 *Methods*, vol. 322, no. 1–2, pp. 28–39, 2007.
- 506 [10] H. P. Sørensen and K. K. Mortensen, “Advanced genetic strategies for recombinant
507 protein expression in *Escherichia coli*,” *J. Biotechnol.*, vol. 115, no. 2, pp. 113–128,
508 2005.
- 509 [11] G. L. Rosano and E. A. Ceccarelli, “Recombinant protein expression in *Escherichia*
510 *coli*: Advances and challenges,” *Front. Microbiol.*, vol. 5, no. APR, pp. 1–17, 2014.
- 511 [12] A. Croset *et al.*, “Differences in the glycosylation of recombinant proteins expressed
512 in HEK and CHO cells,” *J. Biotechnol.*, vol. 161, no. 3, pp. 336–348, 2012.
- 513 [13] G. P. Subedi, R. W. Johnson, H. A. Moniz, K. W. Moremen, and A. Barb, “High Yield
514 Expression of Recombinant Human Proteins with the Transient Transfection of
515 HEK293 Cells in Suspension,” *J. Vis. Exp.*, vol. 106, p. e53568, 2015.
- 516 [14] M. M. Van Oers, G. P. Pijlman, and J. M. Vlak, “Thirty years of baculovirus-insect
517 cell protein expression: From dark horse to mainstream technology,” *J. Gen. Virol.*,
518 vol. 96, no. 1, pp. 6–23, 2015.
- 519 [15] M. Merlin, E. Gecchele, S. Capaldi, M. Pezzotti, and L. Avesani, “Comparative
520 evaluation of recombinant protein production in different biofactories: The green
521 perspective,” *Biomed Res. Int.*, vol. 2014, 2014.

- 522 [16] M. Schröder and R. J. Kaufman, “The Mammalian Unfolded Protein Response,” *Annu.*
523 *Rev. Biochem.*, vol. 74, pp. 739–789, 2005.
- 524 [17] R. L. Wiseman *et al.*, “Flavonol activation defines an unanticipated ligand-binding site
525 in the kinase-RNase domain of IRE1,” *Mol. Cell*, vol. 38, no. 2, pp. 291–304, Apr.
526 2010.
- 527 [18] F. Prischi, P. R. Nowak, M. Carrara, and M. M. U. Ali, “Phosphoregulation of Ire1
528 RNase splicing activity,” *Nat. Commun.*, vol. 5, pp. 1–10, 2014.
- 529 [19] B. Shrestha, C. Smee, and O. Gileadi, “Baculovirus Expression Vector System : An
530 Emerging Host for High-Throughput Eukaryotic Protein Expression,” in *Methods in*
531 *molecular biology (Clifton, N.J.)*, vol. 439, pp. 269–289.
- 532 [20] X. Dong, P. Stothard, I. J. Forsythe, and D. S. Wishart, “PlasMapper: A web server
533 for drawing and auto-annotating plasmid maps,” *Nucleic Acids Res.*, vol. 32, no. WEB
534 SERVER ISS., pp. 660–664, 2004.
- 535 [21] H. Cho *et al.*, “Molecular mechanism by which palmitate inhibits PKR
536 autophosphorylation,” *Biochemistry*, vol. 50, no. 6, pp. 1110–1119, 2011.
- 537 [22] H. C. Feldman, M. Tong, L. Wang, R. Meza-acevedo, A. Theodore, I. Lebedev, ... D.
538 J. Maly, "Structural and Functional Analysis of the Allosteric Inhibition of IRE1 α with
539 ATP-Competitive Ligands," *ACS Chem Biol*, vol. 11, no. 8, pp. 2195–2205, 2016.
- 540 [23] L. Qi, L. Yang, and H. Chen, "Detecting and quantitating physiological endoplasmic
541 reticulum stress," *Methods in enzymology* (1st ed., Vol. 490). Elsevier Inc., 2011.
- 542 [24] R. Volmer, K. van der Ploeg, and D. Ron, "Membrane lipid saturation activates
543 endoplasmic reticulum unfolded protein response transducers through their
544 transmembrane domains," *Proceedings of the National Academy of Sciences*, vol. 110,
545 no. 12, pp. 4628–4633, 2013.
- 546 [25] N. J. Greenfield, “Using circular dichroism spectra to estimate protein secondary
547 structure,” *Nat. Protocols*, vol. 1, no. 6, pp. 2876–2890, 2006.

549 **Supplemental file**

550

551 **I. Preparation of competent *E. coli* DH10Bac cells**

552 **Materials needed:**

- 553 i. *E. coli* DH10Bac (streak from glycerol stock onto a Luria agar plate containing
554 tetracycline/kanamycin/gentamycin, get isolated colonies and inoculate single
555 colony) in LB broth containing tet/kan/gent grown at 37°C at 200 rpm.
556 ii. Ice cold centrifuge tubes, P10, P200, P1000 tips, microcentrifuge tubes and cryovials
557 iii. Refrigerated centrifuge
558 iv. Dimethyl sulfoxide (DMSO)
559 v. FSB buffer: (Sterile filter through a 0.22 µm filter and store at 4°C)

Components	Company	Cat. no	Final concentration
Potassium acetate pH 7.5	Sigma-Aldrich	P1190	10 mM
MnCl ₂	Sigma-Aldrich	M1787	45 mM
CaCl ₂	Sigma-Aldrich	C5670	10 mM
KCl	Sigma-Aldrich	P9541	100 mM
[Co (NH ₃) ₆]Cl ₃	Sigma-Aldrich	481521	3 mM
Glycerol	Sigma-Aldrich	G5516	10 %

560

561 **Protocol:**

- 562 i. Grow *E. coli* DH10Bac cells overnight until the OD is between 0.3-0.6. The LB
563 media should contain kanamycin and tetracycline at the working concentrations
564 listed in Table 8 of the main text.
565 ** It is very important not to overgrow the culture**
566 ii. Cool the cells in wet ice for 10-20 minutes.
567 **From now on the cells should remain always ice cold**
568 iii. Pellet the cells by centrifugation, 10 min at 2500 rpm, 4°C.
569 iv. Resuspend the cells gently in 24 ml of ice-cold FSB.
570 v. Incubate on wet ice for 10-15 minutes.
571 vi. Pellet then cells again as above.
572 vii. Resuspend the cells in 8 ml of cold FSB.
573 viii. Add 280 µL DMSO.
574 ix. Incubate for 5 minutes on wet ice.
575 x. Add 280 µL DMSO.
576 xi. Incubate for further 5 minutes on wet ice.
577 xii. Aliquot the cells in 200-400 µL batches to sterile single-use cryovials.
578 xiii. Store in -80°C.
579 **Do not store in liquid nitrogen**

580

581

582 **II. Preparation of glycerol stocks for *E coli* DH10Bac cells with recombinant bacmid**

583 **Materials needed:**

- 584 i. Glycerol (Sigma-Aldrich, cat # G5516)
585 ii. Cryovials (Sigma-Aldrich, cat# 5000-0020)

586 **Protocol:**

- 587 i. Prepare a 60% glycerol solution in water. Filter sterilize using a 0.22 μm filter or
588 autoclave the solution at 121°C for 15 mins.
589 ii. Grow *E. coli* DH10Bac cells with recombinant bacmid in LB media for 14-16 hrs.
590 The LB media should contain kanamycin, gentamicin and tetracycline at the working
591 concentrations listed in **Table 8** of the main text.
592 iii. Add 750 μL of cells and 250 μL of the glycerol solution to a cryovial.
593 iv. Invert a few times to mix properly.
594 v. Store at -80°C.

595

596

597

598 III. Preparation of recombinant bacmid from *E. coli* DH10Bac cells

599 Materials needed:

- 600 i. PureLink HiPure Plasmid Miniprep kit (buffers R3, L7, N3) (ThermoFisher, cat#
601 K210002)
602 ii. 100% isopropanol

603 Protocol:

- 604 i. For recombinant bacmids, use 15–25 mL of an overnight *E. coli* DH10Bac with
605 recombinant bacmid grown in Luria Broth.
606 ii. Pellet the cells at $5000 \times g$ for 7 minutes to harvest the cells. Remove all medium and
607 wash with PBS if necessary.
608 iii. Add 0.4 mL Resuspension Buffer (R3) with RNase A to the cell pellet in the tube and
609 resuspend the cells. Gently shake the tube until the cell suspension is homogeneous.
610 iv. Add 0.4 mL Lysis Buffer (L7). Place the cap on the tube and ensure it is secure. Mix
611 gently by inverting the capped tube until the lysate mixture is thoroughly
612 homogenous. **Do not vortex.**
613 v. Incubate the lysate at room temperature for 5 minutes. **Do not exceed 5 minutes.**
614 vi. Add 0.4 mL Precipitation Buffer (N3) and mix immediately by inverting the tube
615 until the mixture is thoroughly homogeneous. **Do not vortex.** Centrifuge the lysate at
616 $>12000g$ for 10 mins at RT.

617 **Don't load onto the column provided with the kit. It decreases yield of bacmid and*
618 *does not increase the quality of bacmid obtained**

- 619 vii. Take the supernatant gently without disturbing the pellet Add 0.63mL ice cold
620 isopropanol to the supernatant. Mix well and incubate at RT for 15 mins.

621 **Alternatively, keep overnight at -20°C for precipitation**

- 622 viii. Centrifuge tube at $>12000g$ for 30 mins

623 ix. Air dry the pellet for 10 mins, then resuspend the purified bacmid DNA in 60 uL
624 water.

- 625 x. Solubilize bacmid DNA for 1 hr at 65°C or 4°C overnight.

626 **4°C overnight is much better than 65°C**

- 627 xi. Measure concentration of bacmid with Nanodrop.

628

629